




           This thesis focuses on the importance of the heme catabolic pathway in chronic 
hepatitis C (HCV). The aim is mainly to investigate, whether expresion/activity of key 
enzymes of the heme catabolic pathway, heme oxygenase (HMOX) and biliverdin reductase 
(BLVRA) in the liver and blood (study A) or  promoter variations of HMOX1 and UDP-
glucuronosyltransferase (UGT1A1) (study B) may be associated with the progression of 
fibrosis and may also predict antiviral treatment outcome in patients chronically infected with 
HCV. 
        We set up a new sensitive method to quantify HMOX activity by reduction gas 
chromatography. We developed and extensively validated RealTime PCR assay for HMOX 
and BLVRA expression in the liver and peripheral blood leucocytes (PBL). The (GT)n and 
(TA)n dinucleotide variations in HMOX1 and UGT1A1 gene promoters, respectively, were 
determined by fragment analysis.  
       No association was detected between either expression of HMOX/BLVRA or the HMOX1/ 
UGT1A1 promoter variants and the individual histological stages of liver disease in the HCV 
positive patients. A marked difference in BLVRA expression in PBL between the sustained 
responders (SVR) and patients with treatment failure (NVR) was detected before antiviral 
treatment and during the follow-up. Our data suggests, that BLVRA basal expression in PBL 
may be an independent predictor of SVR. 
 
 
